Journal article

Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

Ajay K Nooka, Katja Weisel, Niels WCJ van de Donk, David Routledge, Paula Rodriguez Otero, Kevin Song, Hang Quach, Natalie Callander, Monique C Minnema, Suzanne Trudel, Nicola A Jackson, Christoph M Ahlers, Ellie Im, Shinta Cheng, L Smith, Nahi Hareth, Geraldine Ferron-Brady, Maria Brouch, Rocio Montes de Oca, Sofia Paul Show all



Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibi..

View full abstract


Awarded by GSK

Funding Acknowledgements

Study funded by GSK (study 208887); belamaf drug linker technology licensed from Seagen Inc.; belamaf monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa; nirogacestat gamma-secretase inhibitor produced by and used in collaboration with SpringWorks Therapeutics, Inc. AK Nooka received consultancy fees from Adaptive Technologies, Amgen, Bristol-Myers Squibb (BMS), Celgene, GlaxoSmithKline (GSK), Janssen, Karyopharm, Oncopeptides, Sanofi and Takeda; research support from Amgen, Janssen, and Takeda; and personal fees from GSK. K Weisel received consultancy fees and honoraria from Adaptive, Amgen, BMS, Celgene, GSK, Janssen, Karyopharm, Sanofi and Takeda; and research funding from Amgen, Celgene, Janssen and Sanofi. Nvd Donk received research support from Amgen, BMS, Celgene, Janssen and Novartis; and serves in advisory boards for Amgen, Bayer, BMS, Celgene, Janssen, Novartis, Roche, Servier and Takeda. D Routledge received consultancy fees from Celgene and Sandoz; and honoraria from Amgen, BMS, Celgene and Sandoz. PR Otero received honoraria from Amgen, Celgene, GSK, Janssen, Kite Pharma and Sanofi; and consulting fees from AbbVie, Celgene, GSK, Janssen, Kite Pharma, Oncopeptides, Sanofi and Takeda. K Song received consultancy fees from Amgen, Celgene and Takeda; research funding from Celgene and Janssen; and honoraria from Amgen, Celgene, Janssen, Otsuka and Takeda. H Quach received consultancy fees from Amgen, Celgene, GSK, Janssen and Karyopharm; research funding from Amgen, Celgene and Sanofi; and honoraria from Amgen, Celgene, GSK, Janssen and Karyopharm. N Callander received research funding from Cellectar. MC Minnema received funding from Celgene and honoraria from Amgen, Celgene, Gilead, Janssen and Servier. S Trudel received consultancy fees from Amgen, Celgene and GSK; research funding from Amgen, Celgene, Genentech, GSK and Janssen; and honoraria from Amgen, Celgene, Janssen, Karyopharm, Sanofi and Takeda. S Cheng and LM Smith are paid employees of SpringWorks Therapeutics (SWTX) and have SWTX stocks and shares. N Hareth has no conflicts of interest to declare. NA Jackson, CM Ahlers, E Im, G Ferron-Brady, M Brouch, RMd Oca, S Paul, B Holkova, I Gupta and BE Kremer are paid employees of GSK and have GSK stocks and shares. P Richardson has served on advisory committees for AbbVie, Celgene, GSK, Janssen, Karyopharm, Oncopeptides, Sanofi and Takeda; and has received research funding from Takeda, Celgene and BMS. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.